
Sino Capital is an investment bank advising Chinese corporate clients on cross-border M&A.
Sino Capital concentrates on middle-market cross-border M&A and works several transaction structures at once, including direct acquisitions, auctions, investment projects, and cross-border financing, rather than a single deal template. Its China origination reaches more than 200 listed companies and over 200 privately-owned companies and funds, and the firm assists more than 30 Chinese clients a year to locate overseas targets or buyers.
Execution outside Asia runs through an office in Lausanne and senior advisors based in Boston and Geneva, supported by advisors recruited from international private equity and investment banking. Client work is concentrated in chemicals, environmental protection, healthcare, and high-end manufacturing, and the leadership team has completed over US$2 billion in M&A and capital raising transactions.
Source: sinocapital.com.hk
Sino Capital generates mandates through direct relationships rather than self-serve or online channels, and its origination rests on a China network of more than 200 listed companies and over 200 privately-owned companies and funds. The firm assists more than 30 Chinese clients a year to locate overseas targets or buyers.
Cross-border mandates are also worked from an office in Lausanne and from senior advisors based in Boston and Geneva. Client work concentrates in chemicals, environmental protection, healthcare, and high-end manufacturing, where the firm finds overseas targets or buyers for Chinese listed companies.
Source: sinocapital.com.hk
Sino Capital positions itself as one of the few Asian investment banks built around non-auction, off-market bilateral M&A for middle-market clients. Its origination rests on a China network of more than 200 listed companies and over 200 privately-owned companies and funds, and it runs mandates from a Hong Kong base with an office in Lausanne and senior advisors based in Boston and Geneva.
The firm sells advisory rather than capital: cross-border M&A advisory, private placement, debt arrangement, and corporate restructuring, with client work concentrated in chemicals, environmental protection, healthcare, and high-end manufacturing. It staffs those mandates with senior advisors drawn from international private equity and investment banking, and its leadership team has completed over US$2 billion in M&A and capital raising transactions.
Source: sinocapital.com.hk